Cargando…
Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease
Coronary heart disease treatment with HMG-CoA reductase inhibitors has been very successful. There is increasing interest in adding other lipid lowering therapy, primarily as additional therapy onto HMG-CoA reductase therapy. This paper will examine two of the more popular secondary agents, ezetimib...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Libertas Academica
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978935/ https://www.ncbi.nlm.nih.gov/pubmed/21079754 http://dx.doi.org/10.4137/CMC.S5970 |